glp-1 receptor agonist and dpp-4 inhibitor combination not recommended inhibitors GLP-1RAs: cardiovascular safety and benefits | Military Medical Research Clinical Use of DPP-4 Inhibitors
Description
Compared with exenatide, lixisenatide is generally well tolerated, with a lower incidence of hypoglycemia, lower immune response at the injection site, and less side effects such as nausea and vomiting
Side effects included nausea (44%), vomiting (24%), diarrhea (30%), constipation (24%), abdominal pain (20%), headache (14%), fatigue (11%), dizziness (8%), abdominal distension (7%), and belching (7%)
Exendin-4 (exenatide), a GLP-1 peptide encoded by lizard genes that is resistant to DPP-4-mediated catalytic degradation, received FDA approval in 2005 and became the first GLP-1RA available for public use
Curr Med Res Opin 2016;32:251262 [DOI] [PubMed] [Google Scholar] 50.Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE
Glucagon-like peptide-1 or GLP-1 is native to the body and is released from the small intestine after a meal ingestion
